-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-1012.1 in Seasonal Influenza
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-1012.1 in Seasonal Influenza report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MRNA-1012.1 in Seasonal InfluenzaDrug Details:mRNA-1012.1 is under development for the prevention of seasonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inobrodib in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Inobrodib in Metastatic Breast Cancer Drug Details:Inobrodib (CCS-1477) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inobrodib in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Inobrodib in Myelodysplastic Syndrome Drug Details:Inobrodib (CCS-1477) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inobrodib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Inobrodib in Non-Small Cell Lung Cancer Drug Details:Inobrodib (CCS-1477) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Inobrodib in Refractory Acute Myeloid Leukemia Drug Details: Inobrodib (CCS-1477) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inobrodib in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Inobrodib in Relapsed Acute Myeloid Leukemia Drug Details: Inobrodib (CCS-1477) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trehalose in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trehalose in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trehalose in Amyotrophic Lateral Sclerosis Drug Details: Trehalose is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ranibizumab biosimilar in Diabetic Retinopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ranibizumab biosimilar in Diabetic Retinopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ranibizumab biosimilar in Diabetic Retinopathy Drug Details: Ranibizumab (Ximluci) is a humanized...
-
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...